Sarepta Therapeutics (SRPT) Tops Q1 EPS by 23c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Sarepta Therapeutics (SRPT) Data 'Positive but Some Questions Remain' - Mizuho
May 3, 2021 1:43 PM EDTMizuho Securities analyst Difei Yang reiterated a Buy rating and $160.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company presented new data from its next-generation exon skipping PPMO at the 30mg dose.
Yang commented, "The data was in line with our "base case"... More
Needham & Company Reiterates Buy Rating on Sarepta Therapeutics (SRPT) on Positive 5051 Update
May 3, 2021 11:58 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $166.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company reported updated clinical results from its multi-dose ascending study of SRP-5051, its exon 51 skipping PPMO in Duchenne Muscular Dystrophy (DMD).
Messer commented,... More
Sarepta Therapeutics (SRPT) Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
May 3, 2021 8:50 AM EDTSarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced positive results from Part A of the MOMENTUM study (Study 5051-201), a global, Phase 2, multi-ascending dose clinical trial of SRP-5051, its next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment for patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping.
In biopsies taken at a median of 12 weeks and after only three doses, results from Part A of MOMENTUM study found that the 30 mg/kg of SRP-5051 dosed monthly... More
